NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICU Medical, Inc. ("ICU Medical, Inc.") (NASDAQ:ICUI) concerning possible violations of federal securities laws.

On April 22, 2025, ICU Medical disclosed it had received a warning letter from the FDA citing unauthorized changes to two of its infusion pump products. The warning letter stated that the pumps were "adulterated" and "misbranded" and noted the Company's modifications "can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality. The FDA stated that these changes may have significantly impacted the safety and efficacy of the devices, raising concerns about the adequacy of ICU Medical's regulatory disclosures.

Following this news, shares of ICU Medical, Inc. fell over 4% on the same day. To obtain additional information, go to:

https://zlk.com/pslra-1/icu-medical-inc-lawsuit-submission-form?prid=144979&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire